Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorMassachusetts General Hospital
About this trial
Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we will evaluate for ATTR in patients with HFpEF in order to to determine how frequently this occurs and how we can predict which heart failure patients may have TTR amyloidosis. Our goal is to identify amyloidosis in heart failure patients earlier so that they can start treatment.
Eligibility criteria
Qualifiers
Patients with a confirmed diagnosis of HFpEF.
Age ≥65 years old
Disqualifiers
End stage chronic kidney disease on dialysis (CKD stage 5 as defined as eGFR <15mL/min)
no history of HFrEF (LVEF<40%) with the exception of low LVEF in the setting of acute decompensation, AF RVR, ACS/MI, etc
Negative 99mTc-pyrophosphate scan within a year
Unable to lie down for 15 minutes for the 99mTc-pyrophosphate scan
Trial design
Treatments tested in this trial
- 99mTc-pyrophosphate Scintigraphy
Treatment groups
515 Participants
are divided into 1 treatment groupSponsors and collaborators
Massachusetts General Hospital
Lead sponsor
Akcea Therapeutics
Collaborator
Pfizer
Collaborator
Alnylam Pharmaceuticals
Collaborator
Eidos Therapeutics, a BridgeBio company
Collaborator
Source ClinicalTrials.gov